Research programme: cysteine proteinase inhibitors - NAEJA

Drug Profile

Research programme: cysteine proteinase inhibitors - NAEJA

Alternative Names: Cysteine protease inhibitors research programme - NAEJA; Cysteine proteinase inhibitors research programme - NAEJA; Research programme: cysteine protease inhibitors - NAEJA; SYN 2019; SYN 2448

Latest Information Update: 25 Oct 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NAEJA Pharmaceutical
  • Class
  • Mechanism of Action Cysteine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Periodontal disorders; Postmenopausal osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 25 Oct 2006 Discontinued - Preclinical for Asthma in Canada (PO)
  • 25 Oct 2006 Discontinued - Preclinical for Periodontal disorders in Canada (PO)
  • 25 Oct 2006 Discontinued - Preclinical for Postmenopausal osteoporosis in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top